Ana Livun
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Ana Livun has a total of 52 co-authors. Here are the top co-authors by number of shared publications:
- Tomo Svaguša
Department of Cardiovascular Disease University Hospital Dubrava Zagreb Croatia
5 shared publications - Danijela Grizelj
Dubrava University Hospital, Zagreb, Croatia
4 shared publications - Mario Udovičić
Department of Cardiovascular Diseases, University Hospital Dubrava, 10000 Zagreb, Croatia
4 shared publications - Šime Manola
Dubrava University Hospital, Zagreb, Croatia
4 shared publications - Katica Cvitkušić Lukenda
Josip Juraj Strossmayer University of Osijek, Faculty of Dental Medicine and Health Osijek, Osijek, Croatia
3 shared publications - Blaženka Miškić
Department of Internal Medicine, ‘Dr. Josip Bencevic’ General Hospital, 35000 Slavonski Brod, Croatia
2 shared publications
Latest Publications
- 1 November 2026
- Published by Medicinska Naklada d.o.o. in Cardiologia Croatica
- Vol. 21 (11-12) , 262
Beyond the phenotype: translating cardiomyopathy genetics into clinical decisions
- 1 November 2026
- Published by Medicinska Naklada d.o.o. in Cardiologia Croatica
- Vol. 21 (11-12) , 262
Beyond the phenotype: translating cardiomyopathy genetics into clinical decisions
- Open Access
- 26 May 2026
- Published by Wiley in Journal of Medical Virology
- Vol. 98 (6) , e70984
Multi‐Layered Genomic and Clinical Analysis Identifies Novel Variants, Co‐Occurring Single Nucleotide Polymorphism Pairs, and Clinical Determinants of Host‐Pathogen Interaction in COVID‐19 Severity
Host genetic factors may contribute to COVID‐19 severity. To identify genetic variants influencing COVID‐19 severity progression, whole‐exome sequencing was performed, followed by an exome‐wide association study on 191 hospitalized patients categorized into three severity groups. The analysis identified nine loci surpassing the suggestive significance threshold ( p ≤ 3 × 10 −4 ): rs2180196 ( β = 2.09, TGM1‐RABGGTA ), rs2236232 ( β = −1.37, PLEKHH1 ), rs7886938 ( β = 1.66, FMO6P ), rs2929047 ( β = −1.16, XKR4 ), rs9841237 ( β = 1.21, SI ), rs34357454 ( β = 1.92, NID2 ), rs1005887 ( β = 1.28, DUSP18 ), rs2281880 ( β = −1.11, SUFU ), and rs73061693 ( β = 1.66, TULP2 ). Furthermore, binomial exact test identified 218 SNPs in COVID‐19‐related genes with significant allele frequency differences between severity groups, including 61 novel variants. Of those 218, co‐occurring SNP pairs were identified within specific severity groups, including pairs in JAK1‐PIK3R2 in critical patients and eight pairs in genes IL6 , SERPINE1 , COL5A1, MAPK14, FREM1, C7, GLS, ATP5PO , and RPL7 in severe patients. Clinical data analysis confirmed known risk factors like older age in men and specific comorbidities and revealed distinct therapeutic and biochemical profiles across severity groups. This study confirms known genetic risks and reveals novel variants, providing a more detailed basis for understanding COVID‐19 pathogenesis and for developing genetic diagnostic and prognostic biomarkers.
- 26 May 2026
- Published by Wiley in Journal of Medical Virology
- Vol. 98 (6) , e70984
Open AccessMulti‐Layered Genomic and Clinical Analysis Identifies Novel Variants, Co‐Occurring Single Nucleotide Polymorphism Pairs, and Clinical Determinants of Host‐Pathogen Interaction in COVID‐19 Severity
Host genetic factors may contribute to COVID‐19 severity. To identify genetic variants influencing COVID‐19 severity progression, whole‐exome sequencing was performed, followed by an exome‐wide association study on 191 hospitalized patients categorized into three severity groups. The analysis identified nine loci surpassing the suggestive significance threshold ( p ≤ 3 × 10 −4 ): rs2180196 ( β = 2.09, TGM1‐RABGGTA ), rs2236232 ( β = −1.37, PLEKHH1 ), rs7886938 ( β = 1.66, FMO6P ), rs2929047 ( β = −1.16, XKR4 ), rs9841237 ( β = 1.21, SI ), rs34357454 ( β = 1.92, NID2 ), rs1005887 ( β = 1.28, DUSP18 ), rs2281880 ( β = −1.11, SUFU ), and rs73061693 ( β = 1.66, TULP2 ). Furthermore, binomial exact test identified 218 SNPs in COVID‐19‐related genes with significant allele frequency differences between severity groups, including 61 novel variants. Of those 218, co‐occurring SNP pairs were identified within specific severity groups, including pairs in JAK1‐PIK3R2 in critical patients and eight pairs in genes IL6 , SERPINE1 , COL5A1, MAPK14, FREM1, C7, GLS, ATP5PO , and RPL7 in severe patients. Clinical data analysis confirmed known risk factors like older age in men and specific comorbidities and revealed distinct therapeutic and biochemical profiles across severity groups. This study confirms known genetic risks and reveals novel variants, providing a more detailed basis for understanding COVID‐19 pathogenesis and for developing genetic diagnostic and prognostic biomarkers.
- 1 November 2024
- Published by Medicinska Naklada d.o.o. in Cardiologia Croatica
- Vol. 19 (11-12) , 444
Single-center experience with genetic testing for cardiomyopathies using next-generation sequencing: results, challenges and the future
- 1 November 2024
- Published by Medicinska Naklada d.o.o. in Cardiologia Croatica
- Vol. 19 (11-12) , 444
Single-center experience with genetic testing for cardiomyopathies using next-generation sequencing: results, challenges and the future
- 11 July 2024
- Published by Wiley in Clinical Genetics
- Vol. 106 (5) , 659-660
A rare form of LIM domain‐binding protein 3 (LDB3) mutation causes hypertrophic cardiomyopathy and myofibrillar myopathy type 4
Polymorphisms in LDB3 gene can cause various forms of cardiomyopathy and myofibrillar myopathy 4 (MM4). Patient described in this study presented with a hypertrophic cardiomyopathy (HCM) and distal myopathy suggestive of myofibrillar myopathy 4. Genetic analysis using the TruSight Cardio Sequencing Kit (Illumina) revealed suspected LDB3 variant (c.1435G>A, p.(Gly479Arg)). This is the first case in which polymorphism in LDB3 gene is likely responsible for MM4 and HCM in the same patient.
- 11 July 2024
- Published by Wiley in Clinical Genetics
- Vol. 106 (5) , 659-660
A rare form of LIM domain‐binding protein 3 (LDB3) mutation causes hypertrophic cardiomyopathy and myofibrillar myopathy type 4
Polymorphisms in LDB3 gene can cause various forms of cardiomyopathy and myofibrillar myopathy 4 (MM4). Patient described in this study presented with a hypertrophic cardiomyopathy (HCM) and distal myopathy suggestive of myofibrillar myopathy 4. Genetic analysis using the TruSight Cardio Sequencing Kit (Illumina) revealed suspected LDB3 variant (c.1435G>A, p.(Gly479Arg)). This is the first case in which polymorphism in LDB3 gene is likely responsible for MM4 and HCM in the same patient.
- Open Access
- 11 April 2024
- Published by Walter de Gruyter GmbH in Turkish Journal of Biochemistry
- Vol. 49 (3) , 368-376
Activity of protein C, protein S and antithrombin 3 in COVID-19 patients treated with different modalities of oxygen supplementation
Objectives: COVID-19 in it is more severe form is characterized by a hyperinflammatory condition, hypercoagulation state and the appearance of pulmonary microembolism. In this study we wanted to correlate levels of D-Dimer, protein C, protein S and antithrombin 3 with severity of disease and clinical outcome. Methods: We included 134 of patients who were divided in 3 groups regarding oxygen support (high flow oxygen therapy, mechanical ventilation and oxygen supplementation with nasal cannula or mask). Results: Concentration of D-Dimer, and activity of protein C and antithrombin 3 are presented as mean±SD and differed significantly between patients on mechanical ventilation (3.26 ± 1.15 mg/L, 86 ± 22.55 %, 81.21 ± 17.61 %)/HFNO (2.35 ± 1.68 mg/L, 109.6 ± 26.96 %, 94.67 ± 17.49 %)/BNC (1.37 ± 1.17 mg/L, 116.92 ± 28.16 %, 103.29 ± 15.63 %) with p<0.001 for all parameters. Mortality in oxygen group was 10.9 %, in HFNC group 40.7 % and in mechanical ventilated group 80 %. Conclusions: determination of anticoagulant factors in COVID-19 patients may indicate which of them are at increased risk of developing severe disease, venous thromboembolism and fatal clinical outcome.
- 11 April 2024
- Published by Walter de Gruyter GmbH in Turkish Journal of Biochemistry
- Vol. 49 (3) , 368-376
Open AccessActivity of protein C, protein S and antithrombin 3 in COVID-19 patients treated with different modalities of oxygen supplementation
Objectives: COVID-19 in it is more severe form is characterized by a hyperinflammatory condition, hypercoagulation state and the appearance of pulmonary microembolism. In this study we wanted to correlate levels of D-Dimer, protein C, protein S and antithrombin 3 with severity of disease and clinical outcome. Methods: We included 134 of patients who were divided in 3 groups regarding oxygen support (high flow oxygen therapy, mechanical ventilation and oxygen supplementation with nasal cannula or mask). Results: Concentration of D-Dimer, and activity of protein C and antithrombin 3 are presented as mean±SD and differed significantly between patients on mechanical ventilation (3.26 ± 1.15 mg/L, 86 ± 22.55 %, 81.21 ± 17.61 %)/HFNO (2.35 ± 1.68 mg/L, 109.6 ± 26.96 %, 94.67 ± 17.49 %)/BNC (1.37 ± 1.17 mg/L, 116.92 ± 28.16 %, 103.29 ± 15.63 %) with p<0.001 for all parameters. Mortality in oxygen group was 10.9 %, in HFNC group 40.7 % and in mechanical ventilated group 80 %. Conclusions: determination of anticoagulant factors in COVID-19 patients may indicate which of them are at increased risk of developing severe disease, venous thromboembolism and fatal clinical outcome.
- 1 August 2023
- Published by Medicinska Naklada d.o.o. in Cardiologia Croatica
- Vol. 18 (9-10) , 251
Present and future of calcific aortic valve disease – multiomics approach
- 1 August 2023
- Published by Medicinska Naklada d.o.o. in Cardiologia Croatica
- Vol. 18 (9-10) , 251
Present and future of calcific aortic valve disease – multiomics approach
- 1 November 2022
- Published by Medicinska Naklada d.o.o. in Cardiologia Croatica
- Vol. 17 (9-10) , 265
Results of the clinical genetic testing pilot study for cardiomyopathies conducted in Dubrava University Hospital
- 1 November 2022
- Published by Medicinska Naklada d.o.o. in Cardiologia Croatica
- Vol. 17 (9-10) , 265
Results of the clinical genetic testing pilot study for cardiomyopathies conducted in Dubrava University Hospital
- 1 September 2021
- Published by Medicinska Naklada d.o.o. in Cardiologia Croatica
- Vol. 16 (9-10) , 307
Genetic and personalized approach to valvular heart disease
- 1 September 2021
- Published by Medicinska Naklada d.o.o. in Cardiologia Croatica
- Vol. 16 (9-10) , 307
Genetic and personalized approach to valvular heart disease
- 14 September 2017
- Published by Taylor & Francis in Hematology
- Vol. 23 (4) , 201-207
High absolute basophil count is a powerful independent predictor of inferior overall survival in patients with primary myelofibrosis
To investigate the clinical and prognostic significance of absolute basophil count (ABC) in patients with primary myelofibrosis (PMF). We retrospectively investigated 58 patients with PMF treated in our institution in the period from 2006 to 2017. ABC was obtained in addition to other hematological and clinical parameters. Patients were separated into high and low ABC groups using the Receiver operating characteristic curve analysis. ABC was higher in PMF patients than in healthy controls (P < 0.001). Patients with high ABC had higher white blood cells (P < 0.001), higher red cell distribution width (P = 0.035), higher lactate dehydrogenase (P < 0.001), more frequently had circulatory blasts (P < 0.001), constitutional symptoms (P = 0.030) and massive splenomegaly (P = 0.014). ABC was also positively correlated with absolute monocyte count (AMC) (P < 0.001) and other components of differential blood count. There was no difference in ABC regarding driver mutations or degree of bone marrow fibrosis. Univariately, high ABC was significantly associated with inferior overall survival (hazard ratio (HR) 4.79, P < 0.001). This effect remained statistically significant (HR 4.27, P = 0.009) in a multivariate Cox regression model adjusted for age, gender, Dynamic International Prognostic Scoring System (HR 2.6, P = 0.001) and AMC (HR 8.45, P = 0.002). High ABC reflects higher disease activity and stronger proliferative potential of disease. ABC and AMC independently predict survival and therefore seem to reflect different underlying pathophysiologic processes. Hence, both have a potential for improvement of current prognostic scores. Basophils represent a part of malignant clone in PMF and are associated with unfavorable disease features and poor prognosis which is independent of currently established prognostic scoring system and monocytosis.
- 14 September 2017
- Published by Taylor & Francis in Hematology
- Vol. 23 (4) , 201-207
High absolute basophil count is a powerful independent predictor of inferior overall survival in patients with primary myelofibrosis
To investigate the clinical and prognostic significance of absolute basophil count (ABC) in patients with primary myelofibrosis (PMF). We retrospectively investigated 58 patients with PMF treated in our institution in the period from 2006 to 2017. ABC was obtained in addition to other hematological and clinical parameters. Patients were separated into high and low ABC groups using the Receiver operating characteristic curve analysis. ABC was higher in PMF patients than in healthy controls (P < 0.001). Patients with high ABC had higher white blood cells (P < 0.001), higher red cell distribution width (P = 0.035), higher lactate dehydrogenase (P < 0.001), more frequently had circulatory blasts (P < 0.001), constitutional symptoms (P = 0.030) and massive splenomegaly (P = 0.014). ABC was also positively correlated with absolute monocyte count (AMC) (P < 0.001) and other components of differential blood count. There was no difference in ABC regarding driver mutations or degree of bone marrow fibrosis. Univariately, high ABC was significantly associated with inferior overall survival (hazard ratio (HR) 4.79, P < 0.001). This effect remained statistically significant (HR 4.27, P = 0.009) in a multivariate Cox regression model adjusted for age, gender, Dynamic International Prognostic Scoring System (HR 2.6, P = 0.001) and AMC (HR 8.45, P = 0.002). High ABC reflects higher disease activity and stronger proliferative potential of disease. ABC and AMC independently predict survival and therefore seem to reflect different underlying pathophysiologic processes. Hence, both have a potential for improvement of current prognostic scores. Basophils represent a part of malignant clone in PMF and are associated with unfavorable disease features and poor prognosis which is independent of currently established prognostic scoring system and monocytosis.
- Open Access
- 6 December 2014
- Published by American Society of Hematology in Blood
- Vol. 124 (21) , 1883
Genes Involved in Maintaining the Bone Marrow Stroma Are Dysregulated in Patients with Myelofibrosis: Lenalidomide Treatment Upregulates SOCS3
Genes Involved in Maintaining the Bone Marrow Stroma Are Dysregulated in Patients with Myelofibrosis: Lenalidomide Treatment Upregulates SOCS3 Background: Primary myelofibrosis (PMF) is the most aggressive of the myeloproliferative neoplasms (MPNs), a group of genetically and clinically heterogenous yet-related diseases with a functionally disturbed hematopoietic niche. Egress of these cells from the BM in patients with PMF, suggests a change in the crosstalk between hematopoietic stem cells (HSCs) and the BM microenvironment (particularly BM stromal cells). Lenalidomide, an immunomodulatory agent, which modulates inflammatory cytokine secretion, angiogenesis and the expression of adhesion molecules, likely has effects on the BM microenvironment. Methods: We studied the expression of a set of genes involved in the organization of the hematopoietic niche in peripheral blood and bone marrow (BM) mononuclear cell (MNC) samples from 32 patients with PMF who participated in a phase 2 trial of lenalidomide plus prednisone (Quintas-Cardama et al., J Clin Oncol 2009;27:4760-766). Sequential samples taken at 3, 6, 9, 12 and >14 months after starting lenalidomide therapy were also analyzed. Baseline BM samples were available for 9 patients and baseline PB samples available for 12 patients and used for our analysis. Quantitative reverse transcriptase-polymerase chain reaction was performed to measure the expression levels of SPARC, COX-2, CXCR4, Pax5C-terminus, SOCS3 and HIF-1a transcripts. β-actin was used as an internal control. In addition, we compared the gene expression levels at baseline with healthy control samples. Results: We found that at baseline (before treatment) COX-2 was upregulated, while CXCR4, Pax5 C-terminus, SOCS3 and HIF-1a were downregulated when compared with expression in healthy BM MNCs. Expression of SPARC, K-RAS,FOS and SOCS2 were not significantly different. In addition, there were no significant differences in relative gene expression between BM MNC and PB samples. We found no correlation between gene expression and JAK2 mutational status or cytogenetic abnormalities. Treatment with LP significantly increased the expression of SOCS3, suggesting that some of the clinical effects of lenalidomide (i.e., reduction in splenomegaly) may be due to a SOCS3-mediated reduction in JAK signaling. Conclusions: Upregulation of COX-2 and downregulation of CXCR4, Pax5C, SOCS3, and HIF-1a may reflect disruptions in the interactions between cells in the BM microenvironment in MF. Increases in SOCS3 expression upon treatment with lenalidomide may lead to reduced JAK-STAT signaling, which may account for some of its clinical effects in myelofibrosis.
- 6 December 2014
- Published by American Society of Hematology in Blood
- Vol. 124 (21) , 1883
Open AccessGenes Involved in Maintaining the Bone Marrow Stroma Are Dysregulated in Patients with Myelofibrosis: Lenalidomide Treatment Upregulates SOCS3
Genes Involved in Maintaining the Bone Marrow Stroma Are Dysregulated in Patients with Myelofibrosis: Lenalidomide Treatment Upregulates SOCS3 Background: Primary myelofibrosis (PMF) is the most aggressive of the myeloproliferative neoplasms (MPNs), a group of genetically and clinically heterogenous yet-related diseases with a functionally disturbed hematopoietic niche. Egress of these cells from the BM in patients with PMF, suggests a change in the crosstalk between hematopoietic stem cells (HSCs) and the BM microenvironment (particularly BM stromal cells). Lenalidomide, an immunomodulatory agent, which modulates inflammatory cytokine secretion, angiogenesis and the expression of adhesion molecules, likely has effects on the BM microenvironment. Methods: We studied the expression of a set of genes involved in the organization of the hematopoietic niche in peripheral blood and bone marrow (BM) mononuclear cell (MNC) samples from 32 patients with PMF who participated in a phase 2 trial of lenalidomide plus prednisone (Quintas-Cardama et al., J Clin Oncol 2009;27:4760-766). Sequential samples taken at 3, 6, 9, 12 and >14 months after starting lenalidomide therapy were also analyzed. Baseline BM samples were available for 9 patients and baseline PB samples available for 12 patients and used for our analysis. Quantitative reverse transcriptase-polymerase chain reaction was performed to measure the expression levels of SPARC, COX-2, CXCR4, Pax5C-terminus, SOCS3 and HIF-1a transcripts. β-actin was used as an internal control. In addition, we compared the gene expression levels at baseline with healthy control samples. Results: We found that at baseline (before treatment) COX-2 was upregulated, while CXCR4, Pax5 C-terminus, SOCS3 and HIF-1a were downregulated when compared with expression in healthy BM MNCs. Expression of SPARC, K-RAS,FOS and SOCS2 were not significantly different. In addition, there were no significant differences in relative gene expression between BM MNC and PB samples. We found no correlation between gene expression and JAK2 mutational status or cytogenetic abnormalities. Treatment with LP significantly increased the expression of SOCS3, suggesting that some of the clinical effects of lenalidomide (i.e., reduction in splenomegaly) may be due to a SOCS3-mediated reduction in JAK signaling. Conclusions: Upregulation of COX-2 and downregulation of CXCR4, Pax5C, SOCS3, and HIF-1a may reflect disruptions in the interactions between cells in the BM microenvironment in MF. Increases in SOCS3 expression upon treatment with lenalidomide may lead to reduced JAK-STAT signaling, which may account for some of its clinical effects in myelofibrosis.